T-LLy
Showing 1 - 25 of 7,989
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma Trial in Australia, United States (Prednisone, Vincristine,
Recruiting
- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Lymphoma
- Prednisone
- +21 more
-
Palo Alto, California
- +6 more
May 2, 2022
Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in United States (Everolimus, Nelarabine, Cyclophosphamide)
Recruiting
- Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Everolimus
- +3 more
-
Atlanta, Georgia
- +3 more
Aug 18, 2022
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood
Active, not recruiting
- Adult T Acute Lymphoblastic Leukemia
- +7 more
- Bortezomib
- +18 more
-
Birmingham, Alabama
- +211 more
Jan 26, 2022
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome Trial in Worldwide (drug, biological, radiation)
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Asparaginase Erwinia chrysanthemi
- +15 more
-
Birmingham, Alabama
- +219 more
Aug 24, 2022
Precursor Cell Lymphoblastic Leukemia-lymphoma Trial in Spain, United States (Ixazomib)
Withdrawn
- Precursor Cell Lymphoblastic Leukemia-lymphoma
-
Jackson, Mississippi
- +6 more
Sep 24, 2020
T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma Trial (Daratumumab)
Not yet recruiting
- T-cell Acute Lymphoblastic Leukemia
- T-Cell Acute Lymphoblastic Lymphoma
- (no location specified)
Jul 13, 2021
Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CAR-T Therapy
-
Hefei, Anhui, China
- +7 more
Jul 31, 2023
Periodontal Diseases Trial in Turin (Decontamination of the pocket with local doxycycline, Decontamination of the pocket with
Recruiting
- Periodontal Diseases
- Decontamination of the pocket with local doxycycline
- Decontamination of the pocket with mechanical instrumentation
-
Turin, ItalyCIR Dental School
May 17, 2023
Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)
Recruiting
- Multiple Myeloma
- APRIL-BAFF-Bicephali CAR-T cells
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 14, 2023
Spinal Cord Injury Trial in Bronx (Natesto testosterone intranasal gel, Ayr Saline Nasal Gel)
Not yet recruiting
- Spinal Cord Injury
- Natesto testosterone intranasal gel
- Ayr Saline Nasal Gel
-
Bronx, New YorkJames J. Peters VA Medical Center, Bronx, NY
Nov 8, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Cyclophosphamide (Non-IMP, Lymphodepletion)
- +3 more
-
Ulm, Baden-Württemberg, Germany
- +4 more
Jul 24, 2023
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)
Recruiting
- B Cell Malignancies
- Universal CD19-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Wuhan, Hubei, ChinaUnion Hospital, Huazhong University of Science and Technology
Jun 8, 2023
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))
Recruiting
- Advanced Breast Cancer
- +2 more
- Trastuzumab Emtansine (T-DM1)
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (Orca-T,
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Orca-T
- Standard-of-Care
-
Duarte, California
- +13 more
Jan 25, 2023
Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)
Recruiting
- Hematologic Malignancies
- RD13-02 cell infusion
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jun 26, 2023
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Hefei (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of University of Science and Techn
Jun 5, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)
Active, not recruiting
- Leukemia
- Acute Lymphoblastic Leukemia
- gene-modified T cells targeted
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 1, 2023
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and
Recruiting
- Metastatic Breast Cancer
- HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
-
Rome, ItalyFondazione Policlinico A. Gemelli - IRCCS
Jun 22, 2023
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Xuzhou, Jiangsu, ChinaAffiliated hospital of Xuzhou medical college
Jun 7, 2023